Mann takes Seaside trip

Mannkind Corp. (NASDAQ:MNKD) is raising money ahead of its Dec. 29 PDUFA date for Afrezza inhaled insulin, but it's doing so in a way that will let the investors - including CEO Alfred Mann - avoid having to put all the money down at once.

The December milestone will be the second go-around for Afrezza. In March, FDA issued a complete response letter for the product to treat Types I and II diabetes, asking for available data to support its clinical utility as well as information about the comparability of the inhalers...